Article

Updated: FDA Temporarily Removes List Of Hospitals, Providers That Received Products From Mass. Compounder

Just hours after posting it Monday, the Food and Drug Administration removed from its website a list of hospitals and doctors that had received products from the compounding pharmacy now at the center of the fungal meningitis outbreak, saying data may be incorrect.

The agency said it is working to correct the list and will repost once it is completed. Data had been supplied to the agency by the pharmacy, the New England Compounding Center in Massachusetts.

Read the full story: http://bit.ly/Rh58e8

Source: Kaiser Health News

Related Videos
Dr Mingyang Song
Fran Gregory, PharmD, MBA, sitting for a video interview
Casey Koch, PharmD, sitting for a video interview
Dr K. Vish Viswanath
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Raymond Osarogiagbon
1 expert in this video
Dr Kimlin Tam Ashing
1 expert in this video
1 expert in this video
Related Content
COA signage | Image Credit: © Maggie L. Shaw
April 29th 2025

Advancing the Art of Medicine Through Partnership

Maggie L. Shaw
Oncology leaders from Alliance Cancer Specialists, American Oncology Network, CHI St. Vincent, Memorial Sloan Kettering Cancer Center, and New York Cancer & Blood Specialists discuss the power of collaboration in cancer care, highlighting partnerships that enhance patient outcomes and resource sharing in community practices.
managed care cast logo
April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD
On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Alopecia areata. | Image Credit: cattyphoto - stock.adobe.com
April 29th 2025

Study Highlights Unmet Needs in Measuring Patient Experiences in Alopecia Areata

Cameron Santoro
Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported outcome measures (PROMs) specific to alopecia areata (AA), a common hair loss condition with substantial quality of life impacts.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Pharmacy Panel at Asembia ASX25 | Image credit: Pearl Steinzor
April 29th 2025

Pharmacy Leaders Discuss Innovation and Patient-Centered Care at Asembia’s AXS25 Summit

Pearl Steinzor
At Asembia’s AXS25 Summit, industry experts explored how pharmacy is evolving to meet rising patient expectations and navigate a shifting health care environment.
Dupilumab. | Image Credit: Semi - stock.adobe.com
Published: April 29th 2025 | Updated: April 29th 2025

Dupilumab Treatment for Patients With CSU: Insights From Jason Hawkes, MD, MS

Maddi Hebebrand
Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent; Sanofi and Regeneron Pharmaceuticals) in the management of chronic spontaneous urticaria (CSU), a condition with limited therapeutic options over the past decade.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo